Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

Medical Isotope Technology

At BWXT Medical Ltd. (BWXT), our talented scientists and engineers have developed a unique solution to meet the growing demand for medical isotopes needed for diagnostic imaging. Featuring a patent-pending neutron capture process, this innovative technology is designed to produce molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is used globally in more than 40 million medical procedures each year.

Tc-99m Generator

BWXT's prototype Tc-99m generator. Actual size not pictured.

What makes our technology different?

BWXT’s technology yields high concentrations of Tc-99m eluate available from conventional Mo-99 sources without reliance on the irradiation of enriched uranium targets. In stark contrast to traditional fission-based processes, our proprietary technology will mitigate radioactive waste streams and nuclear proliferation concerns and will significantly reduce production and waste costs relative to current market participants.

The Mo-99 produced through our process is housed in BWXT-manufactured Tc-99m generators, from which Tc-99m will be extracted for medical imaging and diagnostic procedures.

How will we meet the demand?

The irradiation of molybdenum targets is required in order to supply medical isotopes. Laurentis Energy Partners, a wholly owned subsidiary of Ontario Power Generation, has been selected to perform these irradiation services and we are proceeding with approval and execution of a definitive agreement. We have also entered into an agreement with the University of Missouri to irradiate proprietary BWXT targets in the Missouri University Research Reactor (MURR) for use in production of Mo-99.

Additionally, BWXT acquired Nordion’s medical isotope business from Sotera Health, the leading global provider of mission-critical services to the healthcare industry. This opportunistic acquisition is a key component of streamlining the implementation of our new technology through the final stages of commercialization.

Through our development of this innovative technology, BWXT seeks to enter the medical isotope and radiopharmaceutical industry and furnish a stable North American-based supply of Mo-99 and Tc-99m. Together, our intellectual property, licensed infrastructure and highly trained and experienced personnel are paramount in creating this lifesaving product.